

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of: Stamm et al

Application No. 09/899,026

Group Art Unit: 1615

Filed: July 6, 2001

Examiner: H. Sheikh

For: FENOFIBRATE PHARMACEUTICAL COMPOSITION HAVING HIGH BIOAVAILABILITY AND METHOD FOR PREPARING IT

Attorney Docket No: 107664.115US3

Assistant Commissioner of Patents

Washington, DC 20231

SECOND TERMINAL DISCLAIMER

Laboratoires Fournier, S.A. certifies that it is the owner of the entire right, title and interest in Application No. 09/899,026, filed July 6, 2001, entitled "FENOFIBRATE PHARMACEUTICAL COMPOSITION HAVING HIGH BIOAVAILABILITY AND METHOD FOR PREPARING IT" (hereafter the "above-identified application") by virtue of an assignment recorded in the U.S. Patent and Trademark Office on June 17, 1998, at Reel 9260, Frame 0797.

Laboratoires Fournier, S.A. certifies that it is the owner of the entire right, title and interest in Application No. 10/078,500 filed February 21, 2002, entitled "FENOFIBRATE PHARMACEUTICAL COMPOSITION HAVING HIGH BIOAVAILABILITY AND METHOD FOR PREPARING IT" by virtue of an assignment recorded in the U.S. Patent and Trademark Office on June 17, 1998, at Reel 9260, Frame 0797.

Laboratoires Fournier, S.A. certifies that it is the owner of the entire right, title and interest in Application No. 10/126,875 filed April 22, 2002, entitled "FENOFIBRATE PHARMACEUTICAL COMPOSITION HAVING HIGH BIOAVAILABILITY AND METHOD FOR PREPARING IT" by virtue of an assignment recorded in the U.S. Patent and Trademark Office on June 17, 1998, at Reel 9260, Frame 0797.

Pursuant to 37 C.F.R. § 1.321, Laboratoires Fournier, S.A. hereby disclaims the terminal part of any patent granted on the above-identified application which would extend beyond the expiration date of the full statutory term of a patent granted on US Application No. 10/078,500

01/16/2003 CBETANCO 00000004 080219 09899026

01 FC:1814

110.00 CH

WASHINGTON 191926v1

13 13 Second Terminal Disclaimer U.S. Application No. 09/899,026 Page 2 of 2

or a patent granted on US Application No. 10/126,875, and hereby agree that any patent so granted on the above-identified application shall be enforceable only for and during such period that the legal title to said patent shall be the same as the legal title to a patent granted on US Application No. 10/078,500 and a patent granted on US Application No. 10/126,875, this agreement to run with any patent granted on the above-identified application and to be binding upon the grantor, its successors or assigns.

Laboratoires Fournier, S.A. does not disclaim any terminal part of any patent granted on the above-identified application prior to the expiration date of the full statutory term of a patent granted on US Application No. 10/078,500 or a patent granted on US Application No. 10/126,875, in the event that a patent granted on US Application No. 10/078,500 or a patent granted on US Application No. 10/126,875 later expires for failure to pay a maintenance fee, is held unenforceable, is found invalid, is statutorily disclaimed in whole or terminally disclaimed under 37 C.F.R. § 1.32(a), has all claims canceled by a reexamination certificate, or is otherwise terminated prior to expiration of its statutory term as presently shortened by any terminal disclaimer, except for the separation of legal title stated above.

Date: November 6, 2002

By:

Edward D. Grieff, Esq. Registration No. 38,898

Hale and Dorr LLP

1455 Pennsylvania Avenue, NW

Washington, DC 20004

WASHINGTON 191926v1